Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Zentek Ltd. is a Canada-based nanotechnology company focused on the research, development, and commercialization of advanced materials and intellectual property derived primarily from graphene and graphene-based nanomaterials. The company operates at the intersection of advanced materials, nanotechnology, and healthcare-related applications, with a strategic emphasis on translating laboratory-scale innovations into licensable technologies and commercial products. Zentek’s core value proposition centers on its proprietary graphene production processes and the development of applications that enhance performance, durability, or safety across multiple industries.
The company’s primary business lines include antimicrobial coatings, corrosion protection technologies, ice-phobic solutions, and graphene-enhanced materials for industrial and healthcare use. Zentek’s revenue model has historically emphasized technology development and strategic partnerships rather than large-scale manufacturing, positioning it as an intellectual property–driven enterprise. Founded in 2008 and originally operating under the name Zenyatta Ventures Ltd., the company rebranded as Zentek Ltd. in 2021 to reflect its broader technology focus beyond mineral development and toward applied nanotechnology and commercialization.
Business Operations
Zentek’s operations are organized around the development and commercialization of proprietary technologies rather than traditional product manufacturing. Key operating focus areas include antimicrobial technology, corrosion protection, ice-phobic coatings, and graphene-based material enhancement, with research and development activities forming the core of its operational expenditures. The company generates value primarily through intellectual property ownership, licensing opportunities, and collaborative development agreements rather than recurring product sales.
The company’s technology portfolio is supported by internally controlled research assets and patents, including processes related to graphene synthesis and functionalization. Zentek operates primarily in Canada, with research collaborations involving academic institutions and third-party laboratories. Its wholly owned subsidiary, Zentek Advanced Materials Corp., is used to house certain intellectual property and facilitate commercialization and partnership activities tied to advanced material technologies.
Strategic Position & Investments
Zentek’s strategic direction emphasizes leveraging its graphene platform to address high-value industrial and healthcare challenges where performance differentiation and regulatory barriers can create defensible market positions. Growth initiatives have focused on advancing late-stage testing, regulatory validation, and partner engagement for antimicrobial and protective coating technologies, particularly those applicable to personal protective equipment and infrastructure protection.
The company has made targeted investments in intellectual property development and has pursued collaborative arrangements rather than large-scale acquisitions. Zentek’s portfolio includes patented and patent-pending technologies related to antimicrobial coatings and material durability enhancements. Emerging areas of focus include healthcare-adjacent applications and infrastructure-related solutions, where graphene’s material properties offer potential advantages in longevity, safety, and cost efficiency. Data inconclusive based on available public sources regarding material revenue contributions from individual technologies.
Geographic Footprint
Zentek is headquartered in Guelph, Ontario, Canada, and its primary operational and research activities are concentrated within Canada. The company maintains a domestic focus for research, regulatory engagement, and early-stage commercialization while pursuing international market relevance through licensing discussions and global intellectual property protection.
Although Zentek does not operate large international facilities, its technologies are intended for deployment across North America, Europe, and other global markets where advanced materials and antimicrobial solutions are in demand. International influence is primarily exercised through patent filings, cross-border research validation, and prospective commercial partnerships rather than direct foreign subsidiaries or manufacturing operations.
Leadership & Governance
Zentek is led by an executive team with experience spanning materials science, capital markets, and technology commercialization. Leadership has articulated a strategic vision centered on disciplined capital allocation, protection of intellectual property, and the transition from research-driven innovation to commercially viable applications through partnerships and licensing.
Key executives include:
- Gregory Fenton – Chief Executive Officer
- Francis Dube – Executive Chairman
- Philip McFadden – Chief Financial Officer
- Dr. Francis Dubé – President
The board and executive leadership emphasize a governance philosophy focused on regulatory compliance, scientific validation, and long-term shareholder value creation through scalable technology platforms rather than near-term production growth.